Androgen receptor antigen density and S-phase fraction in prostate cancer: A pilot study

Prostate Cancer and Prostatic Diseases

Volumn 6, Issue 4, 2003, Pages 294-300

  Abdel Wahab, M ^a   Krishan, A ^a   Milikowski, C ^a   Wahab, A A ^a   Walker, G ^b   Markoe, A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Androgen receptors; Antigen density; S phase fraction

Indexed keywords

ANDROGEN RECEPTOR;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER PATIENT; CELL CYCLE S PHASE; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MALE; PILOT STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE ANALYSIS;

AGED; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; S PHASE; SURVIVAL RATE;

EID: 0347899304     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500672     Document Type: Article

References (43)

1. Jenster G et al. Domains of the human androgen receptor involved in steroid binding, transcriptional activity and subcellular localization. Mol Endocrinol 1991; 5: 1396-1404.
2. Klocker H et al. Androgen receptor mutations in prostate cancer. In: Wirth M, Altwein JE, Schmitz-Drager B, Kuptz S (eds). Molecular Biology of Prostate Cancer. Walter de Gruyter, New York, 1998, pp 81-88.
3. Kazemi-Esfarjani P, Trifiro MA, Pinksy L. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the CAG expanded neuronopathies. Hum Mol Genet 1995; 4: 523-527.
4. Suzuki H. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993; 46: 759-765.
5. Suzuki H et al. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996; 29: 153-161.
6. Nam R et al. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. Invest Urol 2000; 164: 567-572.
7. Gil-Diez de Medina S et al. Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum Pathol 1998; 29: 1005-1012.
8. Watanabe M et al. Genetic alteration in androgen receptor gene in Japanese human prostate cancer. Jpn J Clin Oncol 1997; 27: 389-393.
9. Noordzij MA et al. The prognostic value of pretreatment expression of androgen receptor & bcl-2 in hormonally treated prostate cancer patients. J Urol 1997; 158: 1880-1884.
10. Giovanucci E et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997; 94: 3320-3323.
11. Ingles SA et al. Association of prostate cancer risk with genetic polmorhisms in vitamin D receptors and androgen receptor. J Natl Cancer Inst 1997; 89: 166-170.
12. Pertschuk LP et al. Immunocytochemical assay for androgen receptors in prostate cancer: a prospective study of 63 cases with long term follow-up. Ann Surg Oncol 1994; 1: 495-503.
13. Pertschuk LP et al. Immunostaining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis. Lab Invest 1995; 73: 302-305.
14. Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 1991; 67: 3057-3064.
15. Sadi MV, Barrack ER. Androgen receptors & growth fraction in metastatic prostate cancer as predictors of time to tumor progression after hormonal therapy. Cancer Surveys 1991; 11: 195-215.
16. De Winter JA et al. Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Pathol 1990; 160: 329-332.
17. Emtage LA, Dunn PJ, Rowse AD. Androgen & progesterone receptor status in benign & neoplastic prostate disease. Study of prevalence and influence on time to progression and survival in prostate cancer treated by hormone manipulation. Br J Urol 1989; 63: 627-633.
18. Prins GS, Sklarew RJ, Pertschuk LP. Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J Urol 1998; 159: 641-649.
19. Takeda H et al. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate cancer. Cancer 1996; 77: 934-940.
20. Kushlinskii NE et al. The prognostic significance of determining androgen receptors in prostatic cancer. Urol Nefrol 1993; 1: 7-10.
21. Van Aubel OG et al. Circulating testosterone, prostatic nuclear androgen receptor and time to progression in patients with metastatic disease of the prostate treated by orchiectomy. Urol Res 1989; 17: 99-102.
22. Benson Jr RC, Gorman PA, Holicky EL, Veneziale CM. Relationship between androgen receptor binding activity in human prostate cancer and clinical response to endocrine therapy. Cancer 1987; 59: 1599-1606.
23. Ennis RD et al. Length of the CAG repeat polymorphism within the androgen receptor gene predicts biochemical (PSA) complete response to neo-adjuvant androgen deprivation in a prospective clinical trial. Int J Radiat Oncol Biol Phys 1999; 45: 356 (Abstract).
24. Kuil CW, Brinkman AO. Androgens, antiandrogens & androgen receptor abnormalities. Eur Urol 1996; 29: 78-82.
25. Redkar AA, Krishan A. Flow cytometric analysis of estrogen, progesterone receptor expression and DNA content in formalin-fixed, paraffin-embedded human breast tumors. Cytometry 1999; 38: 61-69.
26. Krishan A et al. Flow cytometric analysis of andrigen receptor expression in human prostate tumors and benign tissues. Clin Cancer Res 2000; 6: 1922-1930.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
28. Roach M et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 2000; 47: 609-615.
29. Segawa N et al. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int 2001; 51: 452-459.
30. Klocker H et al. Androgen receptor alterations in prostatic carcinoma. Prostate 1994; 25: 266-273.
31. Magi-Galluzzi C et al. Heterogeneity of androgen receptor contenet in advanced prostate cancer. Mod Pathol 1997; 10: 839-845.
32. Vesalainen S et al. Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy. Br J Cancer 1994; 70: 309-314.
33. Eskelinen M et al. DNA ploidy, S phase fraction and G2 fraction as prognostic determinants in prostatic adenocarcinoma. Eur Urol 1991; 20: 62-66.
34. Romics I et al. DNA content of prostatic cancer measured by flow cytometry in patients undergoing radical prostatectomy. Anticancer Res 1995; 15: 1131-1134.
35. Visakorpi T et al. Flow cytometric analysis of DNA ploidy and S-phase fraction from prostate carcinomas: implications for prognosis and response to endocrine therapy. Br J Cancer 1991; 64: 578-582.
36. Astrom L et al. S-phase fraction related to prognosis in localized prostate cancer. No specific significance of chromosome 7 gain or deletion of 7q31.1. Int J Cancer 1998; 79: 553-559.
37. Mora LB et al. Stage B prostate cancer: Correlation of DNA ploidy analysis with histological and clinical parameters. Cancer Control 199; 60: 587-591.
38. Ahlgren G, Flakmer U, Gadaleanu V, Abrahamsson PA. Evaluation of DNA ploidy combined with a cytometric proliferation index of imprints from core needle biopsies in prostate cancer. Eur Urol 1999; 36: 314-319.
39. Centeno BA et al. Flow cytometric analysis of DNA ploidy, percent S-phase fraction, and total proliferative fraction as prognostic indicators of local control and survival following radiation therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 1994; 30: 309-315.
40. Koivisto P. Aneuploidy and rapid cell proliferation in recurrent prostate cancers with androgen receptor gene amplification. Prostate Cancer Prostatic Dis 1997; 1: 21-25.
41. Kaltz-Wittmer C et al. FISH Analysis of gene aberrations (MYC, CCND1, ERBB2, RB and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Investig 2000; 80: 1455-1464.
42. Henshall SM et al. Altered expression of androgen receptor in malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 2001; 61: 423-427.
43. Pilepich MV et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic adenocarcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45: 616-623.